<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanrd.clo-cecomdfalt.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [[](https://stanford.cloud-cme.com/defaultas?=038044)
7. Please do not delete this instruction.

-->
### Database Entries (Jan 31)
White KM, Rosales R, et int., and Garc√≠a-Sastre A. [‚ÄúPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.‚Äù](/search/?article=White21) _Science (New York, N.Y.)_, None. [doi.org/10.1126/science.abf4058](https://doi.org/10.1126/science.abf4058). \[[PubMed33495306](https://www.ncbi.nlm.nih.gov/pubmed/33495306/)\]
### [linial Trials (Jan 28)]a/pdates/#clinical.trials)
[7 linicaltrials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-28)
### Database Entries (Jan 25)
Gottlieb RL, Nirula A, et int., and Skovronsky DM. [‚ÄúEffect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19.‚Äù](/search/?article=Gottlieb21) _JAMA_, 2021. [doi.org/10.1001/jama.2021.0202](https://doi.org/10.1001/jama.2021.0202). \[[PubMed33475701](https://www.ncbi.nlm.nih.gov/pubmed/33475701/)\]
### [Clinical Trials (Jan 21nical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-21)
### Database Entries (Jan 19)
Davies SP, Mycroft-West CJ, et int., and Richardson A. [‚ÄúThe hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models.‚Äù](/search/?article=Davies21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.10.426114](https://doi.org/10.1101/2021.01.10.426114).
### Database Entries (Jan 19)
Kim C, Ryu D, et int., and Lee S. [‚ÄúA therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.‚Äù](/search/?article=Kim21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20602-5](https://doi.org/10.1038/s41467-020-20602-5). \[[PubMed33436577](https://www.ncbi.nlm.nih.gov/pubmed/33436577/)\]
### Database Entries (Jan 19)
McCallum M, Marco AD, et int., and Veesler D. [‚ÄúN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.‚Äù](/search/?article=McCallum21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.14.426475](https://doi.org/10.1101/2021.01.14.426475).
### Database Entries (Jan 19)
Tada T, Fan C, et int., and Landau NR. [‚ÄúAn ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.‚Äù](/search/?article=Tada20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.108528](https://doi.org/10.1016/j.celrep.2020.108528). \[[PubMed33326798](https://www.ncbi.nlm.nih.gov/pubmed/33326798/)\] \[[PMC7705358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705358/)\]
### Database Entries (Jan 15)
Biering SB, Van Dis E, et int., and Stanley SA. [‚ÄúScreening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2.‚Äù](/search/?article=Biering20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.30.424862](https://doi.org/10.1101/2020.12.30.424862).
### [Clinical Trials (Jan 14)](/g/a#c.trials)
[13 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-14)
### Database Entries (Jan 12)
Kirti R, Roy R, et int., and Sarfaraz A. [‚ÄúIvermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial.‚Äù](/search/?article=Kirti21) _medRxiv_, 2021. [doi.org/10.1101/2021.01.05.21249310](https://doi.org/10.1101/2021.01.05.21249310).

### [Clinical Trials (Jan 07)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-07)

### Database Entries (Jan 05)
Sauer M, Park Y, et int., and Veesler D. [‚ÄúStructural basis for broad coronavirus neutralization.‚Äù](/search/?article=Veesler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.29.424482](https://doi.org/10.1101/2020.12.29.424482).
### Database Entries (Jan 05)
Winkler ES, Gilchuk P, et int., and Diamond MS. [‚ÄúHuman neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.‚Äù](/search/?article=Winkler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.28.424554](https://doi.org/10.1101/2020.12.28.424554).
### [Clinical Trials (Dec 31)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-31)
### Database Entries (Dec 30)
Ashhurst AS, Tang AH, et int., and Payne RJ. [‚ÄúPotent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L.‚Äù](/search/?article=Ashhurst20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.23.424111](https://doi.org/10.1101/2020.12.23.424111).
### Database Entries (Dec 28)
[‚ÄúA Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.‚Äù](/search/?article=ACTIV-3_LY-CoV55520) New England Journal of Medicine, 2020. [doi.org/10.1056/NEJMoa2033130](https://doi.org/10.1056/NEJMoa2033130).
### Database Entries (Dec 25)
Xie X, Muruato AE, et int., and Shi P. [‚ÄúA nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.‚Äù](/search/?article=Xie20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19055-7](https://doi.org/10.1038/s41467-020-19055-7). \[[PubMed33060595](https://www.ncbi.nlm.nih.gov/pubmed/33060595/)\] \[[PMC7567097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/)\]
### [Clinical Trials (Dec 24)](/page/updates/#clinical.trials)
[8 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-24)pates/" should be shorten to "/i oapage/updates/".

6. Try not to include plain links such as [https://stanford.clordoud-cme.com/default.aspx?P=0&EID=38?=.3044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=3804ulsp4).
   Please include readable content in the bracket, e.g. [videi.[io](https://or.cludcme.com/4).

7. Please do not delete this instruction.

-->
### Database Entries (Dec 18)
Weinreich DM, Sivapalasingam S, et int., and Yancopoulos GD. [‚ÄúREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.‚Äù](/search/?article=Weinreich20) _The New England journal of medicine_, 2020. [doi.org/10.1056/nejmoa2035002](https://doi.org/10.1056/nejmoa2035002). \[[PubMed33332778](https://www.ncbi.nlm.nih.gov/pubmed/33332778/alsP04)
###  nical Trials (Dec hiospaedatescliical.trialsebe.uenliaal t from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounndscinl-ria/?ate=2020017)

### Database Entries (Dec 17)
Eslami G, Mousaviasl S, et int., and Mobarak S. [‚ÄúThe impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.‚Äù](/search/?article=Eslami20) _Journal of Antimicrobial Chemotherapy_, 2020. [doi.org/10.1093/jac/dkaa331](https://doi.org/10.1093/jac/dkaa331). \[[PubMed32812051](https://www.ncbi.nlm.nih.gov/pubmed/32812051/)\] \[[PMC7529105](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529105/)\]
### Database Entries (Dec 16)
Hahn F, Wangen C, et int., and Marschall M. [‚ÄúIMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.‚Äù](/search/?article=Hahn20) _Viruses_, 2020. [doi.org/10.3390/v12121394](https://doi.org/10.3390/v12121394). \[[PubMed33291455](https://www.ncbi.nlm.nih.gov/pubmed/33291455/)\]
### Database Entries (Dec 16)
Painter WP, Holman W, et int., and Painter GR. [‚ÄúHuman Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2.‚Äù](/search/?article=Painter20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.20235747](https://doi.org/10.1101/2020.12.10.20235747).
### Database Entries (Dec 16)
Puhl AC, Fritch EJ, et int., and Ekins S. [‚ÄúRepurposing the Ebola and Marburg tus Inh Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.‚Äù](/search/?article=Puhl20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.01.407361](https://doi.org/10.1101/2020.12.01.407361). \[[PubMed33299990](https://www.ncbi.nlm.nih.gov/pubmed/33299990/)\] \[[PMC7724658](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724658/)\]
### Database Entries (Dec 16)
Cox RM, Wolf JD, and Plemper RK. [‚ÄúTherapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=Cox20) _Nature Microbiology_, 2020. [doi.org/10.1038/s41564-020-00835-2](https://doi.org/10.1038/s41564-020-00835-2). \[[PubMed33273742](https://www.ncbi.nlm.nih.gov/pubmed/33273742/)\]
### Database Entries (Dec 14)
Calistri A, Luganini A, et int., and Parolin C. [‚ÄúThe new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2.‚Äù](/search/?article=Calistri20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.06.412759](https://doi.org/10.1101/2020.12.06.412759).
### Database Entries (Dec 14)
Tree JA, Turnbull JE, et int., and Carroll MW. [‚ÄúUnfractionated heparin inhibits live wild‚Äêtype SARS‚ÄêCoV‚Äê2 cell infectivity at therapeutically relevant concentrations.‚Äù](/search/?article=Tree20) _British Journal of Pharmacology_, 2020. [doi.org/10.1111/bph.15304](https://doi.org/10.1111/bph.15304). \[[PubMed33125711](https://www.ncbi.nlm.nih.gov/pubmed/33125711/)\]

### Database Entries (Dec 11)
Abdelnabi R, Foo CS, et int., and Neyts J. [‚ÄúMolnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model.‚Äù](/search/?article=Abdelnabi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.419242](https://doi.org/10.1101/2020.12.10.419242).
### Database Entries (Dec 11)
Arabi YM, Shalhoub S, et int., and Fowler R. [‚ÄúRibavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.‚Äù](/search/?article=Arabi19)¬†_Clinical Infectious Diseases_,¬†2019.¬†[doi.org/10.1093/cid/ciz544](https://doi.org/10.1093/cid/ciz544).¬†\[[PubMed31925415](https://www.ncbi.nlm.nih.gov/pubmed/31925415/)\]¬†\[[PMC7108209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108209/)\]
### Database Entries (Dec 11)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011). \[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\] \[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Database Entries (Dec 11)
Johnson RF, Bagci U, et int., and Marasco WA. [‚Äú3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.‚Äù](/search/?article=Johnson16) _Virology_, 2016. [doi.org/10.1016/j.virol.2016.01.004](https://doi.org/10.1016/j.virol.2016.01.004). \[[PubMed26828465](https://www.ncbi.nlm.nih.gov/pubmed/26828465/)\] \[[PMC4769911](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769911/)\]
### Database Entries (Dec 11)
Kawase M, Shirato K, et int., and Matsuyama S. [‚ÄúSimultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry.‚Äù](/search/?article=Kawase12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.00094-12](https://doi.org/10.1128/jvi.00094-12). \[[PubMed22496216](https://www.ncbi.nlm.nih.gov/pubmed/22496216/)\] \[[PMC3393535](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535/)\]
### Database Entries (Dec 11)
Lu L, Liu Q, et int., and Jiang S. [‚ÄúStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.‚Äù](/search/?article=Lu14) _Nature Communications_, 2014. [doi.org/10.1038/ncomms4067](https://doi.org/10.1038/ncomms4067). \[[PubMed24473083](https://www.ncbi.nlm.nih.gov/pubmed/24473083/)\] \[[PMC7091805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091805/)\]
### Database Entries (Dec 11)
O'Keefe BR, Giomarelli B, et int., and McCray PB. [‚ÄúBroad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae.‚Äù](/search/?article=OKeefe10) _Journal of Virology_, 2009. [doi.org/10.1128/jvi.02322-09](https://doi.org/10.1128/jvi.02322-09). \[[PubMed20032190](https://www.ncbi.nlm.nih.gov/pubmed/20032190/)\] \[[PMC2820936](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820936/)\]
### Database Entries (Dec 11)
Vatansever EC, Yang K, et int., and Liu WR. [‚ÄúBepridil is potent against SARS-CoV-2 In Vitro.‚Äù](/search/?article=Vatansever20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.23.112235](https://doi.org/10.1101/2020.05.23.112235). \[[PubMed32511370](https://www.ncbi.nlm.nih.gov/pubmed/32511370/)\] \[[PMC7263498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263498/)\]
### [Clinical Trials (Dec 10)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-10)

### Database Entries (Dec 09)
Sch√§fer A, Muecksch F, et int., and Sheahan TP. [‚ÄúAntibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.‚Äù](/search/?article=Schafer20) _Journal of Experimental Medicine_, 2020. [doi.org/10.1084/jem.20201993](https://doi.org/10.1084/jem.20201993). \[[PubMed33211088](https://www.ncbi.nlm.nih.gov/pubmed/33211088/)\] \[[PMC7673958](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673958/)\]
### Database Entries (Dec 09)
H√∂rnich BF, Gro√ükopf AK, et int., and Hahn AS. [‚ÄúSARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation and are not inhibited by Bromhexine.‚Äù](/search/?article=Hornich20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.25.221135](https://doi.org/10.1101/2020.07.25.221135).
### Database Entries (Dec 04)
Ar√©valo A, Pagotto R, et int., and Crispo M. [‚ÄúIvermectin reduces coronavirus infection in vivo: a mouse experimental model.‚Äù](/search/?article=Arevalo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.02.363242](https://doi.org/10.1101/2020.11.02.363242).
### Database Entries (Dec 04)
Clausen TM, Sandoval DR, et int., and Esko JD. [‚ÄúSARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.‚Äù](/search/?article=Clausen20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.033](https://doi.org/10.1016/j.cell.2020.09.033). \[[PubMed32970989](https://www.ncbi.nlm.nih.gov/pubmed/32970989/)\] \[[PMC7489987](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/)\]
### Database Entries (Dec 04)
Kumar R, Khandelwal N, et int., and Kumar N. [‚ÄúEmetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibitinginteraction of viral mRNAwith eIF4E: An in vitro study.‚Äù](/search/?article=Kumar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.29.401984](https://doi.org/10.1101/2020.11.29.401984).
### [Clinical Trials (Dec 03)](/page/updates/#clinical.trials)
[17 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-03)
### Database Entries (Dec 03)
Outlaw VK, Bovier FT, et int., and Porotto M. [‚ÄúInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.‚Äù](/search/?article=Outlaw20) _mBio_, 2020. [doi.org/10.1128/mbio.01935-20](https://doi.org/10.1128/mbio.01935-20). \[[PubMed33082259](https://www.ncbi.nlm.nih.gov/pubmed/33082259/)\] \[[PMC7587434](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587434/)\]
### Database Entries (Dec 03)
Udwadia ZF, Singh P, et int., and Tandon M. [‚ÄúEfficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.‚Äù](/search/?article=Udwadia20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.11.142](https://doi.org/10.1016/j.ijid.2020.11.142). \[[PubMed33212256](https://www.ncbi.nlm.nih.gov/pubmed/33212256/)\] \[[PMC7668212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/)\]

### [Published preprints - week of November 30](/page/updates/#published.preprints)
[Rosenke K](/search/?article=Rosenke20b);[Weisblum Y](/search/?article=Weisblum20);[Glasgow20](/search/?article=Glasgow20);[Xiao20](/search/?article=Xiao20);[Luban20](/search/?article=Luban20);[Liu20g](/search/?article=Liu20g)

### Database Entries (Nov 29)
de Melo GD, Lazarini F, et int., and Bourhy H. [‚ÄúAnti-COVID-19 efficacy of ivermectin in the golden hamster.‚Äù](/search/?article=Melo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.21.392639](https://doi.org/10.1101/2020.11.21.392639).
### Database Entries (Nov 29)
Schloer S, Brunotte L, et int., and Rescher U. [‚ÄúDrug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Schloer20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.16.342410](https://doi.org/10.1101/2020.10.16.342410).
### Database Entries (Nov 29)
Touret F, Driouich J, et int., and Nougair√®de A. [‚ÄúPreclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.‚Äù](/search/?article=Touret20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.17.386904](https://doi.org/10.1101/2020.11.17.386904).
### Database Entries (Nov 29)
Wang M, Zhao Y, et int., and Hu K. [‚ÄúTreatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.‚Äù](/search/?article=Wang20n) _Clinical Infectious Diseases_, 2020. [doi.org/10.1093/cid/ciaa1417](https://doi.org/10.1093/cid/ciaa1417). \[[PubMed32955081](https://www.ncbi.nlm.nih.gov/pubmed/32955081/)\] \[[PMC7543328](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543328/)\]
### [Clinical Trials (Nov 26)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-26)
### Database Entries (Nov 26)
Simonovich VA, Burgos Pratx LD, et int., and Belloso WH. [‚ÄúA Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.‚Äù](/search/?article=Simonovich20) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2031304](https://doi.org/10.1056/nejmoa2031304). [PubMed33232588](https://www.ncbi.nlm.nih.gov/pubmed/33232588/)
### Database Entries (Nov 25)
Busnadiego I, Fernbach S, et int., and Hale BG. [‚ÄúAntiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.‚Äù](/search/?article=Busnadiego20) _mBio_, 2020. [doi.org/10.1128/mbio.01928-20](https://doi.org/10.1128/mbio.01928-20). \[[PubMed32913009](https://www.ncbi.nlm.nih.gov/pubmed/32913009/)\] \[[PMC7484Nov 23)
Clementi N, Criscuolo E, et int., and Mancini N. [‚ÄúCombined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.‚Äù](/search/?article=Clementi20) _Frontiers in Microbiology_, 2020. [doi.org/10.3389/fmicb.2020.01704](https://doi.org/10.3389/fmicb.2020.01704). \[[PubMed32754147](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484541/)\]
### Database Entries (Nov 25)
Jagannathan P, Andrews J, et int., and Singh U. [‚ÄúPeginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.‚Äù](/search/?article=Jagannathan20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.18.20234161](https://doi.org/10.1101/2020.11.18.20234161).

### Database Entries (Nov 24)
AlQahtani M, Abdulrahman A, et int., and Abduljalil M. [‚ÄúRandomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.‚Äù](/search/?article=AlQahtani20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.02.20224303](https://doi.org/10.1101/2020.11.02.20224303).
### Database Entries (Nov 24)
Bajpai M, Kumar S, et int., and Sarin SK. [‚ÄúEfficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.‚Äù](/search/?article=Bajpai20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.25.20219337](https://doi.org/10.1101/2020.10.25.20219337).
### Database Entries (Nov 24)
Fu L, Ye F, et int., and Gao GF. [‚ÄúBoth Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.‚Äù](/search/?article=Fu20d) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18233-x](https://doi.org/10.1038/s41467-020-18233-x). \[[PubMed32887884](https://www.ncbi.nlm.nih.gov/pubmed/32887884/)\] \[[PMC7474075](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474075/)\]
### Database Entries (Nov 24)
Hoffman RL, Kania RS, et int., and Taggart B. [‚ÄúDiscovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.‚Äù](/search/?article=Hoffman20) _Journal of Medicinal Chemistry_, 2020. [doi.org/10.1021/acs.jmedchem.0c01063](https://doi.org/10.1021/acs.jmedchem.0c01063). \[[PubMed33054210](https://www.ncbi.nlm.nih.gov/pubmed/33054210/)\] \[[PMC7571312](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571312/)\]
### Database Entries (Nov 24)
Joyner MJ, Bruno KA, et int., and Wright RS. [‚ÄúSafety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients‚Äù](/search/?article=Joyner20c) _Mayo Clinic Proceedings_, 2020. [doi.org/10.1016/j.mayocp.2020.06.028](https://doi.org/10.1016/j.mayocp.2020.06.028). \[[PubMed32861333](https://www.ncbi.nlm.nih.gov/pubmed/32861333/)\] \[[PMC7368917](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368917/)\]

### Database Entries (Nov 23)
Clementi N, Scagnolari C, et int., and Filippini A. [‚ÄúNaringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Clementi20b) _Pharmacological Research_, 2020. [doi.org/10.1016/j.phrs.2020.105255](https://doi.org/10.1016/j.phrs.2020.105255). \[[PubMed33096221](https://www.ncbi.nlm.nih.gov/pubmed/33096221/)\] \[[PMC7574776](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574776/)\]
### [Published preprints - week of November 23](/page/updates/#published.preprints)
[Rajter JC](/search/?article=Rajter20)ubmed/32754147/)\] \[[PMC7365881](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365881/)\]
### Database Entries (Nov 23)
Doi Y, Hibino M, et int., and Kondo M. [‚ÄúA Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.‚Äù](/search/?article=Doi20b) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01897-20](https://doi.org/10.1128/aac.01897-20). \[[PubMed32958718](https://www.ncbi.nlm.nih.gov/pubmed/32958718/)\]
### Database Entries (Nov 23)
Libster R, Perez Marc G, et int., and Polack FP. [‚ÄúPrevention of severe COVID-19 in the elderly by early high-titer plasma.‚Äù](/search/?article=Libster20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.20.20234013](https://doi.org/10.1101/2020.11.20.20234013).
### Database Entries (Nov 23)
Shin YS, Lee JY, et int., and Park CM. [‚ÄúDiscovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.‚Äù](/search/?article=Shin20) _Bioorganic & Medicinal Chemistry Letters_, 2020. [doi.org/10.1016/j.bmcl.2020.127667](https://doi.org/10.1016/j.bmcl.2020.127667). \[[PubMed33160024](https://www.ncbi.nlm.nih.gov/pubmed/33160024/)\] \[[PMC7640924](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640924/)\]
### Database Entries (Nov 23)
Pan H, Peto R, et int., and Swaminathan S. [‚ÄúRepurposed antiviral drugs for COVID-19 ‚Äìinterim WHO SOLIDARITY trial results.‚Äù](/search/?article=WHO20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Nov 23)
Xiang Y, Nambulli S, et int., and Shi Y. [‚ÄúVersatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.‚Äù](/search/?article=Xiang20) _Science_, 2020. [doi.org/10.1126/science.abe4747](https://doi.org/10.1126/science.abe4747). \[[PubMed33154108](https://www.ncbi.nlm.nih.gov/pubmed/33154108/)\]
### [Press Release (Nov 22)](/page/updates/#press.release)
[Casirivimab and imdevimab EUA fact sheet for healthcare providers](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201122.pdf)0&EID=.locecodefault.s?=03804).

7. PlatsP30)

 ease do not delete this instructi

### Database Ensetries (Nov 20)
Andreano E, Nicastri E, et int., and Rappuoli R. [‚ÄúExtremely potent human monoclonal antibooo.tbdies from convalescent Covid-19 patients.‚Äù](/search/?article=Andreano20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.07.328302](https://doi.org/10.1101/2020.10.07.328302).
### Database Entries (Nov 20)
Bracken CJ, Lim SA, et int., and Wells JA. [‚ÄúBi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.‚Äù](/search/?article=Bracken20) _Nature Chemical Biology_, 2020. [doi.org/10.1038/s41589-020-00679-1](https://doi.org/10.1038/s41589-020-00679-1). \[[PubMed33082574](https://www.ncbi.nlm.nih.gov/pubmed/33082574/)\]
### Database Entries (Nov 20)
Tortorici MA, Beltramello M, et int., and Veesler D. [‚ÄúUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.‚Äù](/search/?article=Tortorici20) _Science_, 2020. [doi.org/10.1126/science.abe3354](https://doi.org/10.1126/science.abe3354). \[[PubMed32972994](https://www.ncbi.nlm.nih.gov/pubmed/32972994/)\]

### [CliCe lnical Trials (Nov 19)](/page/updapg/updapbr(pgdttes/#clinical.trials)
[9 c106 linical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned C linical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-19)

### Database Entries (Nov 19)
Barnes CO, Jette CA, et int., and Bjorkman PJ. [‚ÄúSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.‚Äù](/search/?article=Barnes20b) _Nature_, 2020. [doi.org/10.1038/s41586-020-2852-1](https://doi.org/10.1038/s41586-020-2852-1). \[[PubMed33045718](https://www.ncbi.nlm.nih.gov/pubmed/33045718/)\]
### Database Entries (Nov 19)
Van Damme E, De Meyer S, et int., and Van Loock M. [‚ÄúIn Vitro Activity of Itraconazole Against SARS-CoV-2.‚Äù](/search/?article=Damme20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.13.381194](https://doi.org/10.1101/2020.11.13.381194).
### Database Entries (Nov 19)
Gendrot M, Andreani J, et int., and Pradines B. [‚ÄúIn Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.‚Äù](/search/?article=Gendrot20) _Molecules_, 2020. [doi.org/10.3390/molecules25215064](https://doi.org/10.3390/molecules25215064). \[[PubMed33142770](https://www.ncbi.nlm.nih.gov/pubmed/33142770/)\] \[[PMC7663271](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7663271/)\]
### Database Entries (Nov 19)
Wang S, Peng Y, et int., and Liu D. [‚ÄúCharacterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.‚Äù](/search/?article=Wang20l) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19568-1](https://doi.org/10.1038/s41467-020-19568-1). \[[PubMed33188207](https://www.ncbi.nlm.nih.gov/pubmed/33188207/)\] \[[PMC7666115](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/)\]

### [Published preprints - week of November 16](/page/updateg/udts/#published.prepreints)
[Hubrlburt NK](/search/?article=Hurlburt20) (_Nature Communications_); [Sacco MD](/search/?article=Sacco20) (_Science Advances_); [Zhang Q](/search/?article=Zhang20e) (_Cell Discovery_)
### Database Entries (Nov 17)
Monk PD, Marsden RJ, et int., and Rodrigues PM. [‚ÄúSafety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.‚Äù](/search/?article=Monk20) _The Lancet Respiratory Medicine_, 2020. [doi.org/10.1016/s2213-2600(20)30511-7](https://doi.org/10.1016/s2213-2600(20)30511-7). \[[PubMed33189161](https://www.ncbi.nlm.nih.gov/pubmed/33189161/)\]
### Database Entries (Nov 17)
Shi Y, Shuai L, et int., and Peng G. [‚ÄúThe Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract.‚Äù](/search/?article=Shi20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.12.380931](https://doi.org/10.1101/2020.11.12.380931).
rate=2020-11-12)

### Database Entries (Nov 13)
Cornelissen L, Hoefsmit E, et int., and Blank CU. [‚ÄúNafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer rias eduction in a hamster model.‚Äù](/search/?article=Cornelissen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.09.372375](https://doi.org/10.1101/2020.11.09.372375).
### Database Entries (Nov 13)
Feld JJ, Kandel C, et int., ang.(d Hansen B. [‚ÄúPeginterferon-lambda for the treatment of COVID-19 in outpatients.‚Äù](/search/?article=Feld20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.09.20228098](https://doi.org/10.1101/2020.11.09.20228098).
### Database Entries (Nov 13)
Lee S, Kim C, et int., and Choi YK. [‚ÄúA Novel NeutralizingA Antibody Targeting Receptor Binding Domain of SARS-CoV-2.‚Äù](/search/?article=Lee20b) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-59639/v1](https://doi.org/10.21203/rs.3.rs-59639/v1).

### [Clinical Trials (Nov 12)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-12)

### [Press Release (Nov 10)](/page/update-0)

### [Pubbed preprints - w eek of November 9](/geudts/#press.release)
[Bamlanivimab EUA Letter of Authorization](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011101.pdf)

### [Press Release (Nov 10)](/page/updates/#press.release)
[Bamlanivimab EUA Letter of Authorization FAQ](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly202011102.pdf)

### [Published preprints - week of November 9](/page/updates/#published.preprintbprints.peer-reviewed.publications)
[Beddingfield BJ](/search/?article=Beddingfield20) (_JACC Basic Transl Sci_); [Chen CZ](/search/?article=Chen20f) (_ACS Pharmacol. Transl. Sci._); [Ghahremanpour MM](/search/?article=Ghahremanpour20) (_ACS Med. Chem. Lett._); [Lou Y](/search/?article=Lou20) (_EJPS_); [Tandon R](/search/?article=Tandon20) (_Journal of Virology_);
### Database Entries (Nov 09)
Westberg M, Su Y, et int., and Lin MZ. [‚ÄúRational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases.‚Äù](/search/?article=Westberg20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.15.275891](https://doi.org/10.1101/2020.09.15.275891).
### Database Entries (Nov 07)
Chi X, Liu X, et int., and Yang W. [‚ÄúHumanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.‚Äù](/search/?article=Chi20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18387-8](https://doi.org/10.1038/s41467-020-18387-8). \[[PubMed32913273](https://www.ncbi.nlm.nih.gov/pubmed/32913273/)\] \[[PMC7483421](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483421/)\]
### Database Entries (Nov 07)
de Vries RD, Schmitz KS, et int., and Porotto M. [‚ÄúIntranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=deVries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.04.361154](https://doi.org/10.1101/2020.11.04.361154).

### [Published preprints - week of November 2](/page/updates/#published.preprintreprints.peer-reviewed.publications)
[Cust√≥dio TF](/search/?article=Custodio20) (_Ncomms_); [Schoof M](/search/?article=Schoof20) (_Science_); [Li W](/search/?article=Li20b) (_PNAS_); [Kreye J](/search/?article=Kreye20) (_Cell_); [Matsuyama S](/search/?article=Matsuyama20) (_JVI_);
### [Clinical Trials (Nov 05)](/page/upgdates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-05)

### Database Entries (Nov 05)
Bojkova D, Bechtel M, et int., and Cinatl J. [‚ÄúAprotinin Inhibits SARS-CoV-2 Replication.‚Äù](/search/?article=Bojkova20c) _Cells_, 2020. [doi.org/10.3390/cells9112377](https://doi.org/10.3390/cells9112377). \[[PubMed33143316](https://www.ncbi.nlm.nih.gov/pubmed/33143316/)\]
### Database Entries (Nov 05)
Li Y, Cao L, et int., and Zhang X. [‚ÄúRemdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models.‚Äù](/search/?article=Li20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.353300](https://doi.org/10.1101/2020.10.26.353300).
### Database Entries (Nov 04)
Cai Y, Xu W, et int., and Jiang S. [‚ÄúGriffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.‚Äù](/search/?article=Cai20b) _Virologica Sinica_, 2020. [doi.org/10.1007/s12250-020-00305-3](https://doi.org/10.1007/s12250-020-00305-3). \[[PubMed33052520](https://www.ncbi.nlm.nih.gov/pubmed/33052520/)\] \[[PMC7554295](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554295/)\]
### Database Entries (Nov 04)
Weisblum Y, Schmidt F, et int., and Bieniasz PD. [‚ÄúEscape from neutralizing antibodies by SARS-CoV-2 spike protein variants.‚Äù](/search/?article=Weisblum20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214759](https://doi.org/10.1101/2020.07.21.214759). \[[PubMed32743579](https://www.ncbi.nlm.nih.gov/pubmed/32743579/)\] \[[PMC7386497](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386497/)\]
### Database Entries (Nov 04)
Yuan S, Yin X,iv doior.102020.t of en, Dis  et int., and Yuen K. [‚ÄúClofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.‚Äù](/search/?article=Yuan20e) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86169/v1](https://doi.org/10.21203/rs.3.rs-86169/v1). \[[PubMed33052331](https://www.ncbi.nlm.nih.gov/pubmed/33052331/)\] \[[PMC7553155](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/)\]
### [Preprints => Peer-Reviewed Publications (Nov 4)](/page/updates/#uprepreints.peer-reviewed.publications)
1 published preprints were added.
### Database Entries (Nov 03)
Bakovic A, Risner K, et int., and Narayanan A. [‚ÄúBrilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.‚Äù](/search/?article=Bakovic20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.29.352450](https://doi.org/10.1101/2020.10.29.352450).
### Database Entries (Nov 03)
Chan CE, Seah SG, et int., and Hanson BJ. [‚ÄúThe Fc-mediated effector functions of a potent SARS-Cn sw-ooV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.‚Äù](/search/?article=Chan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.355107](https://doi.org/10.1101/2020.10.26.355107).
### Database Entries (Nov 03)
Fu Y, Maruyama J, et int., and Allen RD. [‚ÄúProtective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.‚Äù](/search/?article=Fu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.28.359836](https://doi.org/10.1101/2020.10.28.359836).
### Database Entries (Nov 03)
Halfon P, Bestion E, et int., and Schinazi RF. [‚ÄúGNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.‚Äù](/search/?article=Halfon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.327635](https://doi.org/10.1101/2020.10.06.327635). \[[PubMed33052342](https://www.ncbi.nlm.nih.gov/pubmed/33052342/)\] \[[PMC7553169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553169/)\]
### Database Entries (Nov 03)
Hashim HA, Maulood MF, et int., and Abdulamir AS. [‚ÄúControlled randomized c linical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.‚Äù](/search/?article=Hashim20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.26.20219345](https://doi.org/10.1101/2020.10.26.20219345).
### Database Entries (Nov 03)
Li T, Sun L, et int., and Shen X. [‚ÄúBromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‚Äê19: An Open‚ÄêLabel Randomized Controlled Pilot Study.‚Äù](/search/?article=Li20f) _Clinical and Translational Science_, 2020. [doi.org/10.1111/cts.12881](https://doi.org/10.1111/cts.12881). \[[PubMed32881359](https://www.ncbi.nlm.nih.gov/pubmed/32881359/)\]
### Database Entries (Nov 03)
Mellott D, Tseng C, et int., and McKerrow JH. [‚ÄúA cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.‚Äù](/search/?article=Mellott20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.23.347534](https://doi.org/10.1101/2020.10.23.347534).
### Database Entries (Nov 03)
Rosenfeld R, Noy-Porat T, et int., and Mazor O. [‚ÄúPost-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.‚Äù](/search/?article=Rosenfeld20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.354811](https://doi.org/10.1101/2020.10.26.354811).
### Database Entries (Nov 03)
Zandi K, Amblard F, et int., and Schinazi RF. [‚ÄúRepurposing Nucleoside Analogs for Human Coronaviruses.‚Äù](/search/?article=Zandi20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01652-20](https://doi.org/10.1128/aac.01652-20). \[[PubMed33122172](https://www.ncbi.nlm.nih.gov/pubmed/33122172/)\]

### [Preprints => Peer-Reviewed Publications (Nov 3)](/page/updates/#preue.prints.peer-reviewed.publications)

2 published preprints were added.

### Database Entries (Nov 02)
Cao X, Maruyama J, et int., and Allen RD. [‚ÄúDiscovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.‚Äù](/search/?article=Cao20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.27.316174](https://doi.org/10.1101/2020.09.27.316174).

### [Press Release (Oct 30)](/page/updates/#press.release)
[Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201030.pdf)

### [Clinical Trials (Oct 29)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-29)

### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [‚ÄúSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.‚Äù](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]
### [Press Release (Oct 28)](/page/updates/#press.release)
[Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Signifi cantly Reduced Virus Levels and Need for Further Medical Attention](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201028.pdf)

### [Press Release (Oct 26)](/page/updates/#press.release)

[Lilly Statement Regarding NIH‚Äôs ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [‚ÄúRepurposed antiviral drugs for COVID-19 ‚Äìinterim WHO SOLIDARITY trial results.‚Äù](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [‚ÄúEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.‚Äù](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).

### [Clinical Trials (Oct 22)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-22)
### Database Entries (Oct 22)
Rosenke K, Leventhal S, et int., and Stein DA. [‚ÄúInhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers.‚Äù](/search/?article=Rosenke20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.29.319731](https://doi.org/10.1101/2020.09.29.319731). \[[PubMed33024974](https://www.ncbi.nlm.nih.gov/pubmed/33024974/)\] \[[PMC7536879](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536879/)\]
### Database Entries (Oct 22)
Yin W, Luan X, et int., and Xu HE. [‚ÄúStructural basis for repurposing a 100-years-old drug suramin for treating COVID-19.‚Äù](/search/?article=yin20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.328336](https://doi.org/10.1101/2020.10.06.328336).

### [Press Release (Oct 16)](/page/updates/#press.release)
- [IFN Lambda EigerBioPharmaceuticals](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Eiger20201017.pdf)

### [Clinical Trials (Oct 15)](/page/updates/#clinical.trials)
[5 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-15)
e.g. vieord.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### Database Entries (Oct 13)
Olaleye OA, Kaur M, and Onyenaka CC. [‚ÄúAmbroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein‚Äôs Receptor Binding Domain and Recombinant Human ACE2.‚Äù](/search/?article=Olaleye20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.13.295691](https://doi.org/10.1101/2020.09.13.295691). \[[PubMed32995775](https://www.ncbi.nlm.nih.gov/pubmed/32995775/)\] \[[PMC7523101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523101/)\]

### Database Entries (Oct 13)
Kaptein SJF, Jacobs S, et int., and Delang L. [‚ÄúFavipiravir at high doses has potent antiviral activity in  etint. an aer  e noodesn o comoa SARS-CoV-2‚àíinfected hamsters, whereas hydroxychloroquine lacks activity.‚Äù](/search/?article=Kaptein20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2014441117](https://doi.org/10.1073/pnas.2014441117). \[[PubMed33037151](https://www.ncbi.nlm.nih.gov/pubmed/33037151/)\]

### Database Entries (Oct 12)
Arabi YM, Asiri AY, et int., and Alothman A. [‚ÄúInterferon Beta-1b and Lopinavir‚ÄìRitonavir for Middle East Respiratory Syndrome.‚Äù](/search/?article=Arabi20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2015294](https://doi.org/10.1056/nejmoa2015294). \[[PubMed33026741](https://www.ncbi.nlm.nih.gov/pubmed/33026741/)\]
### Database Entries (Oct 12)
Beigel JH, Tomashek KM, et int., and Lane HC. [‚ÄúRemdesivir for the Treatment of Covid-19 ‚Äî Final Report.‚Äù](/search/?article=Beigel20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
### Database Entries (Oct 12)
Cho J, Lee YJ, et int., and Choi J. [‚ÄúAntiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.‚Äù](/search/?article=Cho20) _SREP_, 2020. [doi.org/10.1038/s41598-020-72879-7](https://doi.org/10.1038/s41598-020-72879-7). \[[PubMed33004837](https://www.ncbi.nlm.nih.gov/pubmed/33004837/)\] \[[PMC7530981](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530981/)\]
### Database Entries (Oct 12)
Gilmore K, Zhou Y, et int., and Seeberger PH. [‚ÄúIn vitro efficacy of Artemisinin-based treatments against SARS-CoV-2[Newly added referencetes/#changelog)

Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=GilmoreBrunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.05.32663709.24.310490](https://doi.org/10.1101/2020.10.05.326637).09.24.310490).

### [Preprints => Peer-Reviewed Publications (Oct lading ceestas.

### [oa 12)](/page/updates/#preprints.peer-reviewed.publications)

3 publishNewly added preprints were added.

### [Clinical Trials (Oct 09)](/page/updates/#clinical.trials)
[23 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-08)


### [New spike structures (Oct 08)](/page/spike-structures/#fig11ure.11.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.spike.receptor.binding.domain.rbd.)
Figure 11. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) spike receptor binding domain (RBD).

### [New spike structures (Oct 08)](/page/spike-structures/#fig12ure.12.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.trimeric.spike.)
Figure 12. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) trimeric spike.

### Webinar (Oct 07)
Monoclonal Antibodies for the Prevention and Treatment of COVID 19. [video](https://www.youtube.com/watch?v=YUj9jBlTCrY)

### [Press Release (Oct 07)](/page/updates/#press.-release)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly202010072.pdf)

### Database Eentries (Oct 05)
Ansarin K, Tolouian R, et int., and Chapman KR. [‚ÄúEffect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.‚Äù](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
### Database Eentries (Oct 05)
Wahl A, Gralinski L, et int., and Garcia JV. [‚ÄúAcute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.‚Äù](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
### Database Eentries (Oct 03)
Jones BE, Brown-Augsburger PL, et int., and Falconer E. [‚ÄúLY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.‚Äù](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
### Database Eentries (Oct 03)
Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [‚ÄúBromelain Iference (Sep 29)](/page/updates/#changelog)

Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibits SARS-CoV-2 Iinfection in VeroE6 Cellsvitro.‚Äù](/search/?article=SagarCurreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
### Database Eentries (Oct 03)
Watson A, Ferreira L, et int., and Stroud R. [‚ÄúPeptide Antidotes to SARS-CoV-2 (COVID-19).‚Äù](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Regeneron20200930.pdf)

### [Clinical Trials (Oct 01)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the reg8.25.266437](https://doi.org/10.1101/2020.08.25.266437).

### [New clinical trials (Sep 28)](/page/updates/#new.clinical.trials.sep.28.)

14 clinical trials were added since September 24: [listry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-01)

### Database entries (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [‚ÄúProphylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.‚Äù](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Database entries (Oct 01)
Son J, Huang S, et int., and Ding S. [‚ÄúNitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.‚Äù](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Database entries (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [‚ÄúA potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.‚Äù](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Database entries (Oct 01)
Lin C, Li Y, et int., and Chen J. [‚ÄúCeftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.‚Äù](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Database entries (Oct 01)
Xiao T, Lu J, et int., and Chen B. [‚ÄúA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.‚Äù](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Database entries (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [‚ÄúA proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.‚Äù](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Database entries (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=Brunaugh20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Database entries (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Curreli20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
### Database entries (Sep 25)
new clinical trials](/clinical-trials/?fromDate=2020-09-24).

### [Published preprints (Sep 28)](/page/updates/#published.preprints.sep.16.sep.28.)

3 published preprints were added since September 16.

### [Newly added reference (Sep 25)](/page/updates/#changelog)

ter Ellen ter BM, Dinesh Kumar N, et int., and Smit JM. [‚ÄúResveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.‚Äù](/search/?article=Ellen%20ter20)¬† _bioRxiv_,¬† 2020.¬† [doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).

### Database entries (Sep 24)
Pereda R, Gonz√°lez D, et int., and Dom√≠nguez RE. [‚ÄúTherapeutic Effectiveness of Interferon-Œ±2b Against COVID-19: The Cuban Experience.‚Äù](/search/?article=Pereda20)¬†_Journal of Interferon & Cytokine Research_,¬†2020.¬†[doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124).¬†\[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]

### [Clinical Trials (Sep 24)](/page/updates/#clinical.trials)
[10 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-09-04)

### [New [New spike structure (Sep 24)](/page/updates/#new.spike .structure (S.sep .24)](/page/updates/#features.)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#featuresnew.table.added.sep.24.)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### Database entries (Sep 23)[Newly added reference (Sep 23)](/page/updates/#changelog)

Cao L, Goreshnik I, et int., and Baker D. [‚ÄúDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors.‚Äù](/search/?article=Cao20e)¬† _Science_,¬† 2020.¬† [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909).¬†\[ [PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]

### [Interface update (Sep 22)](/page/updates/#featuresinterface.update.sep.22.)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#papers)

Shafer R. ‚ÄúA SARS-CoVa.sars-cov-2 .antiviral .therapy score card‚Äù _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

### [Preprints => Peer-Reviewed Publications (Sep 16)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.

### Database entries (Sep 15)
Li T, Han X, et int., and Jin A. [‚ÄúA key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.‚Äù](/search/?article=Li20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
### Database entries (Sep 14)
Cohen-Dvashi H, Weinstein J, et int., and Diskin R. [‚ÄúCoronacept ‚Äì a potent immunoadhesin against SARS-CoV-2.‚Äù](/search/?article=Cohen-Dvashi20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.12.247940](https://doi.org/10.1101/2020.08.12.247940).
### Database entries (Sep 14)
Glasgow A, Glasgow J, et int., and Wells JA. [‚ÄúEngineered ACE2 receptor traps potently neutralize SARS-CoV-2.‚Äù](/search/?article=Glasgow20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.31.231746](https://doi.org/10.1101/2020.07.31.231746).¬†\[[PubMed32766586](https://www.ncbi.nlm.nih.gov/pubmed/32766586/)\]¬†\[[PMC7402043](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402043/)\]
### Database entries (Sep 14)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20)¬†_Cell_,¬†2020.¬†[doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011).¬†\[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\]¬†\[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Database entries (Sep 14)
Olaleye OA, Kaur M, et int., and Adebusuyi T. [‚ÄúDiscovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro.‚Äù](/search/?article=Olaleye20)¬†_bioRxiv.score.card.sep.21.)

Shafer R. ‚ÄúA SARS-CoV-2 antiviral therapy score card‚Äù _Global Health & Medicine_,¬† 2020.¬† [doi.org/10.1101/2020.08.14.250480](https://doi.org/10.1101/2020.08.14.250480).¬†\[[PubMed32817951](https://www.ncbi.nlm.nih.gov/pubmed/32817951/)\]¬†\[[PMC7430586](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430586/)\]
### Database entries (Sep 14)
de Vries M, Mohamed AS, et int., and Dittmann M. [‚ÄúComparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.‚Äù](/search/?article=Vries20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.28.272880](https://doi.org/10.1101/2020.08.28.272880).¬†\[[PubMed32869028](https://www.ncbi.nlm.nih.gov/pubmed/32869028/)\]¬†\[[PMC7457613](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/)\]
### Database entries (Sep 14)
Zhang Q, Chen CZ, et int., and Ye Y. [‚ÄúHeparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro.‚Äù](/search/?article=Zhang20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.14.202549](https://doi.org/10.1101/2020.07.14.202549).¬†\[[PubMed32699847](https://www.ncbi.nlm.nih.gov/pubmed/32699847/)\]¬†\[[PMC7373127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373127/)\]35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

<!--stackedit_data:
eyJoaXN0b3J5IjpbMTk3NjkzOTQ2Nl19
-->